MGNX MACROGENICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1125345 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.8%
TTM net income YoY32.1%
TTM EPS YoY33.9%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-70.2%
Net margin-45.4%
FCF margin-36.4%
EBITDA margin-66.4%
Returns
ROE-111.8%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets92.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage-4.52x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $149.50M | $149.96M | $58.75M | $151.94M | $77.45M |
| Cost of revenue | $0 | $847,000 | $619,000 | $3.35M | $2.65M |
| Gross profit | $149.50M | $149.12M | $58.13M | $148.59M | $74.80M |
| R&D expense | $147.17M | $177.19M | $166.58M | $207.03M | $214.58M |
| SG&A expense | $39.16M | $71.05M | $52.19M | $58.95M | $63.01M |
| Operating income | -$72.84M | -$110.58M | -$168.24M | -$121.42M | -$202.79M |
| Interest expense | $8.51M | $1.11M | $1.43M | $0 | $0 |
| Pretax income | -$75.29M | -$66.02M | -$9.06M | -$119.76M | — |
| Income tax | -$672,000 | $944,000 | $0 | $0 | $0 |
| Net income | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -$202.12M |
| EBITDA | -$65.67M | -$103.04M | -$158.60M | -$109.55M | -$191.54M |
| EPS (basic) | -1.18 | -1.07 | -0.15 | -1.95 | -3.37 |
| EPS (diluted) | -1.18 | -1.07 | -0.15 | -1.95 | -3.37 |
| Weighted avg. shares (diluted) | 63.16M | 62.62M | 61.93M | 61.43M | 59.94M |
| Balance sheet | |||||
| Cash & equivalents | $57.22M | $182.84M | $100.96M | $108.88M | $123.47M |
| Receivables | $427,000 | $4.31M | $10.37M | $56.22M | $10.39M |
| Inventory | $7.91M | $0 | $1.22M | $1.45M | $4.39M |
| Current assets | $219.94M | $217.49M | $251.34M | $222.18M | $279.56M |
| PP&E, net | $2.10M | $18.10M | $21.85M | $29.57M | $37.68M |
| Total assets | $256.85M | $261.65M | $298.42M | $280.47M | $335.25M |
| Current liabilities | $43.12M | $55.53M | $56.11M | $48.61M | $74.58M |
| Total liabilities | $201.25M | $145.60M | $145.81M | $138.46M | $95.63M |
| Shareholders' equity | $55.59M | $116.06M | $152.61M | $142.01M | $239.62M |
| Shares outstanding | 63.32M | 62.82M | 62.07M | 61.70M | 61.31M |
| Cash flow statement | |||||
| Operating cash flow | -$81.04M | -$68.37M | -$78.20M | -$86.96M | -$143.83M |
| Capital expenditure | $1.91M | $3.71M | $1.76M | $3.62M | $6.20M |
| Free cash flow | -$82.95M | -$72.08M | -$79.97M | -$90.58M | -$150.03M |
| Investing cash flow | -$114.10M | $149.30M | -$80.08M | $70.72M | -$36.61M |
| Financing cash flow | $69.51M | $960,000 | $150.36M | $1.66M | $122.78M |
| Depreciation & amortization | $7.17M | $7.54M | $9.64M | $11.87M | $11.26M |
| Stock-based compensation | $14.29M | $29.44M | $18.37M | $20.44M | $23.13M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.